Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has issued an announcement.
Imugene Limited has outlined a new capital raising move via a proposed issue of securities on the ASX, signaling its ongoing need to fund development activities in immuno‑oncology. The company remains focused on leveraging the equity and debt markets to support growth and maintain momentum in its cancer therapy pipeline.
Under the proposal, Imugene plans to issue up to 66,576,087 warrants priced at $0.276 each, expiring on 30 April 2031, along with 22,400 convertible notes maturing on 24 January 2030. The placement structure, combining long‑dated warrants and convertible notes, provides the company with near‑term funding and potential future equity inflows while offering investors leveraged exposure to Imugene’s long‑term prospects.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX, focused on developing novel immuno‑oncology therapies. Its primary activities centre on research and clinical development of cancer treatments that harness the immune system, targeting global oncology markets through partnerships and capital markets funding.
Average Trading Volume: 1,547,501
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$44.65M
Learn more about IMU stock on TipRanks’ Stock Analysis page.